Healthcare Providers and Services
Company Overview of AlloSource, Inc.
AlloSource, Inc. operates as a tissue bank that offers standard and customized precision allograft products to the medical community in the United States and internationally. It provides live mesenchymal stem cell transplants/stem cell tissue for surgeries; progressive bone and tissue-based medical products; skin allografts for victims suffering from traumatic burn injuries; a range of demineralized bone matrix (DBM) products; bone growth substitutes, such as DBM and cancellous bone particulates, DBM paste and putty, and bone void fillers; machined and fresh articular allografts; and joint restoration allograft tissue, including fresh osteochondral allografts, tendons, and menisci. The compa...
6278 South Troy Circle
Centennial, CO 80111
Founded in 1994
Key Executives for AlloSource, Inc.
Vice President of Operations
Chairman of the Medical Advisory Board and Senior Medical Director
Compensation as of Fiscal Year 2013.
AlloSource, Inc. Key Developments
Allosource and Humacyte Inc. Become Strategic Manufacturing Partners to Create Investigational Bioengineered Blood Vessels from Tissue Donor Cells
Oct 10 13
AlloSource and Humacyte Inc. announced that they have entered into a long-term strategic manufacturing partnership. According to the agreement, AlloSource will become the sole manufacturing partner to create Humacyte's investigational bioengineered blood vessels being developed for hemodialysis applications. Humacyte, a developer of novel human tissue-based products for potential applications in regenerative medicine and vascular surgery, uses innovative technology to create the first investigational biological replacement vessels that are being developed to be stored "off-the-shelf" for future use. Subject to ongoing research and development and future regulatory approval, Humacyte's investigational bioengineered vessels could be used to create a vascular graft option available for patients on demand. These investigational bioengineered vessels are produced using donated human vascular cells and then decellularized to remove the donor identity from the newly created vessels. This process results in the production of investigational human vascular grafts with the potential to be implanted into any patient at the time of medical need.
AlloSource Launches AlloMend Acellular Dermal Matrix
Aug 15 13
AlloSource announced the launch of a new proprietary allograft, AlloMend Acellular Dermal Matrix (ADM). The new allograft can be used in a broad range of soft tissue surgical procedures, including ventral hernia repair and post-mastectomy reconstruction. AlloMend ADM is created through a proprietary process in which viable cellular elements that are capable of triggering an immune response are removed from donated human skin, leaving a collagen elastin matrix behind. Upon transplantation, the recipient's own cells infiltrate and repopulate this three-dimensional scaffold to begin the revascularization and remodeling process. AlloMend ADM is processed with an exclusive tissue cleansing process without the use of detergents or enzymes. Therefore, no harmful residuals are left in the tissue. Additionally, studies show that AlloMend exceeds the tensile strength - the measure of force needed to break a biomaterial - of the leading acellular dermal matrices.
AlloSource, Inc. Announces Management Changes
Oct 29 12
AlloSource, Inc. announced Elizabeth Hearty's return to AlloSource as Vice President of Operations. Hearty returns to AlloSource with more than 18 years of experience in operations, finance and business management. Prior to returning to AlloSource, Hearty held the position of Chief Executive Officer for LABS, Inc. While with LABS, she dramatically grew the business and helped LABS stay true to its mission of dedication to the organ, eye and tissue industry. In her previous role at AlloSource, Hearty served as Chief Financial Officer and Vice President, giving her a unique, varied perspective of the different facets of the allograft tissue business. In her position as VP of Operations, Hearty will oversee a broad range of AlloSource departments including donor receiving, tissue processing, and supply chain and materials management. She will also supervise the engineering and facilities functions, maintaining operations' primary role of maximizing the donor gift. Dean Elliott, who was serving in a transitional role as the Vice President of Operations, will resume his leadership position as AlloSource's General Counsel and Chief Compliance Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|